Ovid Therapeutics Inc. (OVID)

Import this data to Google Sheets with:

=jivedata("OVID","financials")

Full statements spill as a table. For one cell: =jivedata("OVID","Revenue") or =jivedata("OVID","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Ovid Therapeutics Inc.

OVID • CIK 0001636651

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-59,281.464	$-61,885	$-42,439	$-58,358
Other Nonoperating Income (Expense)	$6,942.505	$35,452	$25,026	$23,868
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-52,338.959	$-26,433	$-17,414	$-34,491
Income Tax Expense (Benefit)	$0	$0	$0	$0
Weighted Average Number of Shares Outstanding, Basic	70,580,604	—	—	70,906,288
Revenue from Contract with Customer, Excluding Assessed Tax	$222,800	$566	$7,252	$1,583
Research and Development Expense	$28,587.884	$36,767	$25,582	$33,596
General and Administrative Expense	$31,085.274	$25,684	$24,109	$26,345
Operating Expenses	$59,673.158	$62,451	$49,691	$59,941

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$27,041.517	$26,301	$13,153	$11,327
Debt Securities, Available-for-sale, Current	$78,791.858	$26,774	$56,482	$105,892
Debt Securities, Available-for-sale, Noncurrent	—	—	$20,812	$52,550
Prepaid Expense and Other Assets, Current	$3,764.332	$2,865	$4,733	$6,398
Equity Securities without Readily Determinable Fair Value, Amount	—	—	$41,961	$42,694
Assets, Current	$109,597.707	$55,940	$74,368	$123,617
Restricted Cash	$1,930.753	$1,931	$1,931	$1,931
Operating Lease, Right-of-Use Asset	$13,894.376	$12,797	$11,610	$10,980
Property, Plant and Equipment, Net	$768.753	$433	$252	$201
Other Assets, Noncurrent	$209.574	$92	$0	$0
Assets	$144,026.783	$92,167	$150,934	$231,973
Liabilities	$56,229.896	$23,941	$20,274	$22,083
Accounts Payable, Current	$3,702.936	$3,191	$1,956	$4,072
Accrued Liabilities, Current	$6,525.235	$5,994	$4,899	$4,424
Operating Lease, Liability, Current	$1,246.119	$1,336	$1,433	$1,484
Liabilities, Current	$11,474.29	$10,522	$8,288	$9,980
Operating Lease, Liability, Noncurrent	$14,755.606	$13,419	$11,986	$11,231
Preferred Stock, Value, Issued	$0.001	$0	$0	$0
Common Stock, Value, Issued	$70.692	$71	$130	$185
Additional Paid in Capital	$365,590.993	$372,489	$452,445	$564,165
Accumulated Other Comprehensive Income (Loss), Net of Tax	$0.702	$-35	$-202	$-750
Retained Earnings (Accumulated Deficit)	$-277,865.501	$-304,299	$-321,713	$-353,710
Stockholders' Equity Attributable to Parent	$87,796.887	$68,226	$130,660	$209,890
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	1,250	1,250	0	0
Common Stock, Shares Authorized	125,000,000	125,000,000	315,000,000	315,000,000
Common Stock, Shares, Issued	70,691,992	71,009,866	130,184,353	184,755,735

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-52,338.959	$-26,433	$-17,414	$-34,491
Net Cash Provided by (Used in) Operating Activities	$-45,780.925	$-55,956	$-38,334	$-54,773
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	—	—	$-167	$-293
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	—	—	$-13,148	$-17,088
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$28,972.27	$28,232	$15,084	$88,012
Payments to Acquire Debt Securities, Available-for-sale	$112,443.15	$73,246	$91,854	$188,799
Equity Securities, FV-NI, Unrealized Gain (Loss)	$2,003.073	$3,349	$21,052	$21,118
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale	$120,000	$128,000	$42,000	$41,000
Payments to Acquire Property, Plant, and Equipment	$40.308	$71	$0	$0
Share-based Payment Arrangement, Noncash Expense	$7,285.192	$6,276	$4,807	$4,781
Payments to Develop Software	$97.147	$90	$0	$0
Depreciation, Depletion and Amortization	$568.282	$613	$273	$84
Net Cash Provided by (Used in) Investing Activities	$-2,580.605	$54,594	$-49,854	$-147,799
Operating Lease, Right-of-Use Asset, Amortization Expense	$1,028.293	$1,097	$1,187	$1,235
IncreaseDecreaseInOperatingLeaseLiability	$-533.946	$-1,246	$-1,336	$-1,383
Proceeds from Issuance of Private Placement	—	—	$75,116	$131,300
Proceeds from Stock Options Exercised	$535.201	$622	$91	$305
Net Cash Provided by (Used in) Financing Activities	$30,535.201	$622	$75,207	$185,777
Increase (Decrease) in Prepaid Expense and Other Assets	$1,385.052	$-899	$1,802	$2,589
Increase (Decrease) in Accounts Payable, Trade	$1,750.026	$-512	$-1,234	$122
Increase (Decrease) in Accrued Liabilities	$2,020.566	$-537	$-1,068	$325

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("OVID","financials")

Full statements spill as a table. For one cell: =jivedata("OVID","Revenue") or =jivedata("OVID","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.